new crosslinked hyaluronan gel
DeviceAt the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
Other names: MateRegen Gel
NCT Number: NCT03353909
Using American Fertility Society classification of intrauterine adhesions, the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesion formation after dilatation and curettage for delayed miscarriage in women without previous dilatation and curettage was examined.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Study Objectives: To evaluate the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesions formation after dilatation and curettage.
Design: Randomized controlled trial. Settings: Six hospitals for maternal and child health care in China. Patients: Three hundred women undergoing dilatation and curettage for delayed miscarriage without previous dilatation and curettage.
Interventions: Women were randomly assigned into either dilatation and curettage alone group or dilatation and curettage plus new crosslinked hyaluronan gel application group with 1:1 allocation.
Measurements and Outcomes: All patients were evaluated using American Fertility Society classification of IUAs during the follow-up diagnostic hysteroscopy, scheduled 3 months after dilatation and curettage procedure. The primary outcome was the number of women with IUAs, and the secondary outcome was the adhesion scores and the severity of IUAs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
The inclusion criteria:
The exclusion criteria:
At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
Other names: MateRegen Gel
Time frame: 3 months after dilatation and curettage
The number of women with intrauterine adhesion
Time frame: 3 months after dilatation and curettage
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (<1/3 cavity with adhesion), 2 points (1/3-2/3 cavity with adhesion) and 4 points (>2/3 cavity with adhesion), high values represent worse outcome
Time frame: 3 months after dilatation and curettage
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 1 point (filmy adhesion), 2 points (filmy & dense adhesion) and 4 points (dense adhesion), high values represent worse outcome
Time frame: 3 months after dilatation and curettage
Evaluated according to American Fertility Society classification of intrauterine adhesion during the follow-up diagnostic hysteroscopy: 0 point (normal), 2 points (hypomenorrhea) and 4 points (amenorrhea), high values represent worse outcome
Time frame: 3 months after dilatation and curettage
The summed score of the adhesion scores of extent of uterine cavity involved, type of adhesion and menstrual pattern; range: 1-12 points, high values represent worse outcome
Time frame: 3 months after dilatation and curettage
Graded according to cumulative adhesion score: Stage I (mild)(1-4 points), Stage II (moderate)(5-8 points) and Stage III (severe)(9-12 points).
BioRegen Biomedical (Changzhou) Co., Ltd
Industry
The Efficacy of A New Crosslinked Hyaluronan Gel in the Prevention of Postoperative Intrauterine Adhesion After Dilatation and Curettage in Women With Delayed Miscarriage: A Prospective, Randomized, Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06924437
Abnormal Uterine Bleeding (AUB), Endometrial Polyp
Sohag, Egypt
View Trial DetailsNCT05394662
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Phoenix, Arizona, United States
View Trial DetailsNCT05414760
Asherman Syndrome, Female Urogenital Diseases
Eindhoven, Netherlands
View Trial DetailsNCT04166500
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Kaohsiung City, Taiwan
View Trial Details